Evidence map›Paper›PMID 32183326›Full record

ArticleJournal of functional biomaterials2020

Development of Scaffolds with Adjusted Stiffness for Mimicking Disease-Related Alterations of Liver Rigidity.

Marc Ruoß, Silas Rebholz, Marina Weimer, Carl Grom-Baumgarten, Kiriaki Athanasopulu, Ralf Kemkemer, Hanno Käß, Sabrina Ehnert, Andreas K Nussler

Open access · goldAbstract read
In one paragraph

Article in Journal of functional biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in bioengineering and biotechnology · 2023
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Marc RuoßDepartment of Traumatology, Siegfried Weller Institute, Eberhard Karls University, 72076 Tübingen, Germany.ORCID 0000-0002-0193-4425
Silas RebholzDepartment of Traumatology, Siegfried Weller Institute, Eberhard Karls University, 72076 Tübingen, Germany.
Marina WeimerDepartment of Traumatology, Siegfried Weller Institute, Eberhard Karls University, 72076 Tübingen, Germany.
Carl Grom-BaumgartenDepartment of Traumatology, Siegfried Weller Institute, Eberhard Karls University, 72076 Tübingen, Germany.
Kiriaki AthanasopuluFaculty of Applied Chemistry, Reutlingen University, 72762 Reutlingen, Germany.
Ralf KemkemerFaculty of Applied Chemistry, Reutlingen University, 72762 Reutlingen, Germany.
Hanno KäßFaculty of Basic Science, University of Applied Sciences Esslingen, 73728 Esslingen am Neckar, Germany.
Sabrina EhnertDepartment of Traumatology, Siegfried Weller Institute, Eberhard Karls University, 72076 Tübingen, Germany.
Andreas K NusslerDepartment of Traumatology, Siegfried Weller Institute, Eberhard Karls University, 72076 Tübingen, Germany.ORCID 0000-0002-6666-6791
Reutlingen University · DEEsslingen University of Applied Sciences · DE

Funding

Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tübingen -
6 · The paper itself

Abstract

Drug-induced liver toxicity is one of the most common reasons for the failure of drugs in clinical trials and frequent withdrawal from the market. Reasons for such failures include the low predictive power of in vivo studies, that is mainly caused by metabolic differences between humans and animals, and intraspecific variances. In addition to factors such as age and genetic background, changes in drug metabolism can also be caused by disease-related changes in the liver. Such metabolic changes have also been observed in clinical settings, for example, in association with a change in liver stiffness, a major characteristic of an altered fibrotic liver. For mimicking these changes in an in vitro model, this study aimed to develop scaffolds that represent the rigidity of healthy and fibrotic liver tissue. We observed that liver cells plated on scaffolds representing the stiffness of healthy livers showed a higher metabolic activity compared to cells plated on stiffer scaffolds. Additionally, we detected a positive effect of a scaffold pre-coated with fetal calf serum (FCS)-containing media. This pre-incubation resulted in increased cell adherence during cell seeding onto the scaffolds. In summary, we developed a scaffold-based 3D model that mimics liver stiffness-dependent changes in drug metabolism that may more easily predict drug interaction in diseased livers.

Indexed as

Arg-Gly-Asp (RGD)-peptidescell attachmentin vitro modelpre-coatingscaffold culturestiffness

Identifiers

PMID32183326
PMCPMC7151584
OpenAlexW3011320329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.